Idecabtagene vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study

被引：0

作者：

Goldschmidt, Hartmut ^{[1
,2
]}

Raje, Noopur ^{[3
]}

Siegel, David ^{[4
]}

Jagannath, Sundar ^{[5
]}

Lonial, Sagar ^{[6
]}

Munshi, Nikhil ^{[7
,8
]}

Moreau, Philippe ^{[9
]}

Cavo, Michele ^{[10
]}

Truppel-Hartmann, Anna ^{[11
]}

Rowe, Everton ^{[12
]}

Huang, Liping ^{[12
]}

Agarwal, Amit ^{[12
]}

Wang, Julie ^{[12
]}

Campbell, Timothy ^{[12
]}

San-Miguel, Jesus ^{[13
]}

Reece, Donna ^{[14
]}

机构：

[1] Univ Heidelberg Hosp, Heidelberg, Germany

[2] Natl Ctr Tumor Dis, Heidelberg, Germany

[3] Massachusetts Gen Hosp, Boston, MA USA

[4] Hackensack Univ Med Ctr, Hackensack, NJ USA

[5] Mt Sinai Hosp, New York, NY USA

[6] Mt Sinai Hosp, New York, NY USA

[7] Harvard Med Sch, LeBow Inst Myeloma Therapeut, Dana Farber Canc Inst, Boston, MA USA

[8] Harvard Med Sch, Jerome Lipper Multiple Myeloma Ctr, Dana Farber Canc Inst, Boston, MA USA

[9] Ctr Hosp Univ Nantes, Nantes, France

[10] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[11] bluebird bio, Cambridge, MA USA

[12] Bristol Myers Squibb, Princeton, NJ USA

[13] Clin Univ Navarra, CIMA, IDISNA, CIBERONC, Navarra, Spain

[14] Princess Margaret Canc Ctr, Toronto, ON, Canada

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

208

引用

页码：50 / 50

页数：1

共 50 条

[1] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
Raje, Noopur S.
Siegel, David S.
Jagannath, Sundar
Lonial, Sagar
Munshi, Nikhil C.
Moreau, Philippe
Goldschmidt, Hartmut
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Huang, Liping
Agarwal, Amit
Wang, Julie
Campbell, Timothy B.
San-Miguel, Jesus F.
Reece, Donna E.
BLOOD, 2020, 136
[2] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of high-risk patient (Pt) subgroups in the KarMMa study
Goldschmidt, H.
Raje, N. S.
Siegel, D.
Jagannath, S.
Lonial, S.
Munshi, N. C.
Moreau, P.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Huang, L.
Agarwal, A.
Wang, J.
Campbell, T. B.
San-Miguel, J.
Reece, D. E.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 18 - 19
[3] Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma
Kansagra, Ankit
Lin, Yi
Berdeja, Jesus G.
Shah, Nina
Oriol, Albert
Yakoub-Agha, Ibrahim
Einsele, Hermann
Rambaldi, Alessandro
Truppel-Hartmann, Anna
Rowe, Everton
Wang, Julie
Agarwal, Amit
Campbell, Timothy B.
Lonial, Sagar
BLOOD, 2020, 136
[4] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
Einsele, Hermann
Berdeja, Jesus
Raje, Noopur
Siegel, David
Lin, Yi
Anderson, Larry, Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy
Jagannath, Sundar
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
[5] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
Einsele, H.
Berdeja, J.
Raje, N. S.
Siegel, D. S.
Lin, Y.
Anderson, L. D., Jr.
Rodriguez-Otero, P.
Manier, S.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Sanford, J.
Wang, J.
Campbell, T. B.
Jagannath, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
[6] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY
Jesus, San-Miguel
Noopur, Raje S.
David, Siegel
Sundar, Jagannath
Sagar, Lonial
Nikhil, Munshi C.
Philippe, Moreau
Hartmut, Goldschmidt
Michele, Cavo
Anna, Truppel-Hartmann
Everton, Rowe
Huang Liping
Amit, Agarwal
Julie, Wang
Timothy, Campbell B.
Donna, Reece E.
HAEMATOLOGICA, 2021, 106 (10) : 77 - 77
[7] Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis
Berdeja, Jesus G.
Raje, Noopur S.
Siegel, David S.
Lin, Yi
Anderson, Larry D., Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Einsele, Hermann
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy B.
Jagannath, Sundar
BLOOD, 2020, 136
[8] KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)
Einsele, H.
Kansagra, A.
Lin, Y.
Berdeja, J.
Shah, N.
Oriol, A.
Yakoub-Agha, I
Rambaldi, A.
Truppel-Hartmann, A.
Rowe, E.
Wang, J.
Agarwal, A.
Campbell, T. B.
Lonial, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 208 - 209
[9] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.
Manier, Salomon
Kansagra, Ankit J.
Anderson, Larry D., Jr.
Berdeja, Jesus G.
Jagannath, Sundar
Lin, Yi
Lonial, Sagar
Shah, Nina
Raje, Noopur S.
Siegel, David Samuel DiCapua
Oriol, Albert
Truppel-Hartmann, Anna
Rowe, Everton
Patel, Payal
Agarwal, Amit
Campbell, Timothy B.
Rodriguez-Otero, Paula
Munshi, Nikhil C.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma in the pivotal phase 2 KarMMa study
Weisel, K.
Manier, S.
Kansagra, A.
Anderson, Jr L. D.
Berdeja, J.
Jagannath, S.
Lin, Y.
Lonial, S.
Shah, N.
Raje, N.
Siegel, D.
Oriol, A.
Truppel-Hartmann, A.
Rowe, E.
Patel, P.
Agarwal, A.
Campbell, T. B.
Rodriguez-Otero, P.
Munshi, N.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 179 - 180

← 1 2 3 4 5 →